Initial Beneficial Ownership · 3/A
AC Immune SA
ACIUNASDAQEQUITYCurrent
Initial Beneficial Ownership
Structured filing — 3/A
ownership.xml
Amendment · This filing reports the amendment as submitted.
Filing details
- Report period
- 2026-10-02
- Original submission
- 2026-10-09
- Issuer
- AC Immune SA
- Issuer CIK
- 0001651625
- Trading symbol
- ACIU
Reporting owner 1
- Name
- Graney Thomas
- Reporting owner CIK
- 0001618275
- Relationship
- Director
- Address
- EPFL INNOVATION PARK, BUILDING B, LAUSANNE, SWITZERLAND, V8, 1015
Non-derivative holdings
| Security | Amount owned | Ownership |
|---|---|---|
| Common Shares | 12,959[F1] | D |
Table key
- D
- Direct
Derivative holdings
| Security | Conversion / exercise price | Exercisable | Expires | Underlying security | Underlying shares | Ownership |
|---|---|---|---|---|---|---|
| Share Option (right to buy) | 2.71 | 2027-06-10 | 2036-10-01 | Common Shares | 19,565 | D |
Table key
- D
- Direct
Footnotes
- F1
- Includes 8,936 common shares underlying outstanding restricted share units.↩ 1
Remarks
Exhibit 24 - Power of Attorney. This Form 3/A is being filed solely to add a copy of the Power of Attorney as Exhibit 24.
Signature 1
- Signed
- /s/ Matthias Maurer, attorney-in-fact for Thomas Graney
- Date
- 2026-10-09
Filed exhibits
- EXHIBIT 24 ↗dp254856_ex24.htm
Company context
AC Immune (NASDAQ: ACIU) is a clinical-stage biopharma company selectively targeting the key pathologic misfolded proteins and pathways that drive neurodegenerative diseases. Building on more than two decades of expertise in the field of misfolded proteins, AC Immune is advancing a diversified portfolio of disease-modifying active immunotherapies and small molecule approaches. AC Immune’s wholly-owned pipeline includes its lead program, ACI-7104, in Phase 2 development for early Parkinson's disease (PD), a progressive neurodegenerative disease affecting c.10 million people worldwide with no approved disease-modifying therapies today. By targeting misfolded alpha-synuclein, a key driver of PD progression, ACI-7104 aims to slow, or halt, the spread of the disease throughout the brain before irreversible neurological damage occurs. The Company is also advancing ACI-19764, an NLRP3 inflammasome inhibitor in Phase 1, and a preclinical intracellular small molecule alpha-synuclein program.